person · Reporting owner
Fenimore Christopher R.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP Finance CFO | August 18, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 18, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,984 |
Ending reported balance
After 2026-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-18 · Exercise / conversion · Acquired 6,283 · Balance 24,583 Row 2 · 2026-08-18 · Tax withholding · Disposed 4,599 · Balance 19,984 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 6,000 |
Reported balance
After 2026-08-18 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-18 · Exercise / conversion · Disposed 6,283 · Balance 6,000 F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 1,574 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,574 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 1,897 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,897 F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust. |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Daugh | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 25 |
| Common StockSEC Table I · non-derivative | Indirectby Trust for Son | 25 |
Reported balance
Holding disclosure · report date 2026-08-18 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 25 |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held in a trust for the benefit of the reporting person's spouse. The reporting person and the reporting person's spouse are trustees of the trust.
F2: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 676 | $642.39 | $434,255.64 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 10 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,815 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 676 shares of Company stock on July 21, 2020 at prices ranging from $642.25 to $642.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 855 | $641.58 | $548,550.90 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,491 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 855 shares of Company stock on July 21, 2020 at prices ranging from $641.00 to $641.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 113 | $640.61 | $72,388.93 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,346 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 75 | $639.64 | $47,973.00 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,459 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 75 shares of Company stock on July 21, 2020 at prices ranging from $639.22 to $639.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 306 | $638.51 | $195,384.06 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,534 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 306 shares of Company stock on July 21, 2020 at prices ranging from $638.44 to $638.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 154 | $637.88 | $98,233.52 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,840 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 154 shares of Company stock on July 21, 2020 at prices ranging from $637.79 to $637.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 216 | $636.56 | $137,496.96 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,994 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 216 shares of Company stock on July 21, 2020 at prices ranging from $636.56 to $636.57. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on July 21, 2020 at each separate price. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $179.13 | $0.00 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · derivative · entry 22 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 10,000 shares Expires 2022-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,224 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · derivative · entry 21 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,224 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,224 | $52.03 | $115,714.72 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,210 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 6,291 | $655.57 | $4,124,190.87 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,986 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| July 20, 2020 Filed Jul 22, 2020 20:31 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 10,000 | $179.13 | $1,791,300.00 |
DisclosureSEC source: 0001237899-20-000035 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 294 | $596.36 | $175,329.84 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 18 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,277 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 294 shares of Company stock on June 16, 2020 at prices ranging from $596.00 to $596.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 403 | $595.50 | $239,986.50 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 17 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,571 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 403 shares of Company stock on June 16, 2020 at prices ranging from $595.08 to $595.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 747 | $594.35 | $443,979.45 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 16 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,974 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 747 shares of Company stock on June 16, 2020 at prices ranging from $594.05 to $594.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 109 | $593.25 | $64,664.25 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 15 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,721 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 214 | $592.20 | $126,730.80 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 14 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,830 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 214 shares of Company stock on June 16, 2020 at prices ranging from $592.01 to $592.41. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 233 | $591.61 | $137,845.13 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 13 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,044 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 233 shares of Company stock on June 16, 2020 at prices ranging from $591.06 to $591.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 153 | $590.70 | $90,377.10 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,277 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 153 shares of Company stock on June 16, 2020 at prices ranging from $590.00 to $590.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 147 | $588.80 | $86,553.60 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,430 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 147 shares of Company stock on June 16, 2020 at prices ranging from $588.60 to $588.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 373 | $587.55 | $219,156.15 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 10 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,577 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 373 shares of Company stock on June 16, 2020 at prices ranging from $587.05 to $587.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 413 | $586.54 | $242,241.02 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,950 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 413 shares of Company stock on June 16, 2020 at prices ranging from $586.29 to $586.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 130 | $585.76 | $76,148.80 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,363 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 130 shares of Company stock on June 16, 2020 at prices ranging from $585.11 to $585.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $584.62 | $57,877.38 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,493 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 111 | $583.06 | $64,719.66 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,592 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 18 | $582.69 | $10,488.42 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,703 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 18 shares of Company stock on June 16, 2020 at prices ranging from $582.53 to $582.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 112 | $581.40 | $65,116.80 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,721 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 112 shares of Company stock on June 16, 2020 at prices ranging from $581.39 to $581.40. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on June 16, 2020 at each separate price. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,226 | $0.00 Strike: $52.03 | $0.00 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · derivative · entry 24 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,226 shares Expires 2021-12-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F16 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,180 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · derivative · entry 23 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,180 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 2,180 | $30.63 | $66,773.40 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,670 | $587.90 | $2,157,593.00 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,653 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 20:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 7,226 | $52.03 | $375,968.78 |
DisclosureSEC source: 0001708138-20-000074 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,200 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · derivative · entry 19 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,180 Underlying: Common Stock · 1,200 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 68 | $497.99 | $33,863.32 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 14 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,097 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 37 | $494.16 | $18,283.92 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 13 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,165 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 174 | $493.24 | $85,823.76 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 12 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,202 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 174 shares of Company stock on April 1, 2020 at prices ranging from $493.14 to $493.49. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 134 | $492.45 | $65,988.30 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 11 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,376 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 134 shares of Company stock on April 1, 2020 at prices ranging from $492.07 to $492.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 70 | $491.65 | $34,415.50 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 10 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,510 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 201 | $489.48 | $98,385.48 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 9 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,580 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 201 shares of Company stock on April 1, 2020 at prices ranging from $489.17 to $489.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 137 | $488.76 | $66,960.12 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 8 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,781 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 137 shares of Company stock on April 1, 2020 at prices ranging from $488.57 to $488.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 3 | $484.14 | $1,452.42 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 7 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,918 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 124 | $483.58 | $59,963.92 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,921 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 124 shares of Company stock on April 1, 2020 at prices ranging from $483.35 to $483.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 1, 2020 at each separate price. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 62 | $482.09 | $29,889.58 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 5 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,045 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 58 | $480.28 | $27,856.24 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 4 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,107 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 69 | $479.00 | $33,051.00 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 3 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,165 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 63 | $478.77 | $30,162.51 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 2 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,234 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 20:05 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 1,200 | $30.63 | $36,756.00 |
DisclosureSEC source: 0001237899-20-000015 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| January 24, 2020 Filed Jan 27, 2020 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 500 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001237899-20-000005 · edgardoc.xml · derivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,380 Underlying: Common Stock · 500 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| January 24, 2020 Filed Jan 27, 2020 21:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 500 | $30.63 | $15,315.00 |
DisclosureSEC source: 0001237899-20-000005 · edgardoc.xml · nonDerivative · entry 1 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,097 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2019 Filed Dec 23, 2019 21:02 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 400 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001708138-19-000014 · edgardoc.xml · derivative · entry 6 Fenimore Christopher R. · CIK 0001697422 · VP Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,880 Underlying: Common Stock · 400 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option award vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.